Literature DB >> 31896591

Insights into the Gene Expression Profiles of Active and Restricted Red/Green-HIV+ Human Astrocytes: Implications for Shock or Lock Therapies in the Brain.

Venkata Viswanadh Edara1, Anuja Ghorpade1, Kathleen Borgmann2.   

Abstract

A significant number of people living with human immunodeficiency virus type 1 (HIV-1) suffer from HIV-associated neurocognitive disorders (HAND). Many previous studies investigating HIV in astrocytes as a heterogenous population have established the relevance of astrocytes to HIV-associated neuropathogenesis. However, these studies were unable to differentiate the state of infection, i.e., active or latent, or to evaluate how this affects astrocyte biology. In this study, the pseudotyped doubly labeled fluorescent reporter red/green (R/G)-HIV-1 was used to identify and enrich restricted and active populations of HIV+ astrocytes based on the viral promoter activity. Here, we report that the majority of human astrocytes restricted R/G-HIV-1 gene expression early during infection and were resistant to reactivation by vorinostat and interleukin 1β. However, actively infected astrocytes were inducible, leading to increased expression of viral proteins upon reactivation. R/G-HIV-1 infection also significantly decreased the cell proliferation and glutamate clearance ability of astrocytes, which may contribute to excitotoxicity. Moreover, transcriptome analyses to compare gene expression patterns of astrocyte harboring active versus restricted long terminal repeats (LTRs) revealed that the gene expression patterns were similar and that the active population demonstrated more widespread and robust changes. Our data suggest that harboring the HIV genome profoundly alters astrocyte biology and that strategies that keep the virus latent (e.g., block and lock) or those that reactivate the latent virus (e.g., shock and kill) would be detrimental to astrocyte function and possibly augment their contributions to HAND.IMPORTANCE More than 36 million people are living with HIV-1 worldwide, and despite antiretroviral therapy, 30 to 50% of the people living with HIV-1 suffer from mild to moderate neurocognitive disorders. HIV-1 reservoirs in the central nervous system (CNS) are challenging to address due to low penetration of antiretroviral drugs, lack of resident T cells, and permanent integration of provirus into neural cells such as microglia and astrocytes. Several studies have shown astrocyte dysfunction during HIV-1 infection. However, little is known about how HIV-1 latency affects their function. The significance of our research is in identifying that the majority of HIV+ astrocytes restrict HIV expression and were resistant to reactivation. Further, simply harboring the HIV genome profoundly altered astrocyte biology, resulting in a proinflammatory phenotype and functional changes. In this context, therapeutic strategies to reactivate or silence astrocyte HIV reservoirs, without excising proviral DNA, will likely lead to detrimental neuropathological outcomes during HIV CNS infection.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  HIV-1 latency; HIV-associated neurocognitive disorders (HAND); RNA sequencing; astroglia; neuroinflammation; transcriptomics; viral reservoirs

Mesh:

Substances:

Year:  2020        PMID: 31896591      PMCID: PMC7158706          DOI: 10.1128/JVI.01563-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

1.  HIV-1 Tat depresses DNA-PK(CS) expression and DNA repair, and sensitizes cells to ionizing radiation.

Authors:  Yi Sun; Yue-Chen Huang; Qin-Zhi Xu; Hui-Ping Wang; Bei Bai; Jian-Li Sui; Ping-Kun Zhou
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-01       Impact factor: 7.038

2.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features.

Authors:  Yang Liao; Gordon K Smyth; Wei Shi
Journal:  Bioinformatics       Date:  2013-11-13       Impact factor: 6.937

3.  Characterization of a novel binding site for the human immunodeficiency virus type 1 envelope protein gp120 on human fetal astrocytes.

Authors:  M Ma; J D Geiger; A Nath
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus.

Authors:  Bettina Groschel; Frederic Bushman
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia.

Authors:  Xiaojuan Liu; Malabendu Jana; Subhajit Dasgupta; Sreenivas Koka; Jun He; Charles Wood; Kalipada Pahan
Journal:  J Biol Chem       Date:  2002-08-07       Impact factor: 5.157

6.  A scaling normalization method for differential expression analysis of RNA-seq data.

Authors:  Mark D Robinson; Alicia Oshlack
Journal:  Genome Biol       Date:  2010-03-02       Impact factor: 13.583

7.  Cell cycle G2/M arrest through an S phase-dependent mechanism by HIV-1 viral protein R.

Authors:  Ge Li; Hyeon U Park; Dong Liang; Richard Y Zhao
Journal:  Retrovirology       Date:  2010-07-07       Impact factor: 4.602

8.  Differential transcriptional regulation by human immunodeficiency virus type 1 and gp120 in human astrocytes.

Authors:  D Galey; K Becker; N Haughey; A Kalehua; D Taub; J Woodward; M P Mattson; A Nath
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

9.  Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain.

Authors:  Annadora J Bruce-Keller; Ashok Chauhan; Filomena O Dimayuga; Jillian Gee; Jeffrey N Keller; Avindra Nath
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

10.  Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity.

Authors:  Michelle A Sama; Diana M Mathis; Jennifer L Furman; Hafiz Mohmmad Abdul; Irina A Artiushin; Susan D Kraner; Christopher M Norris
Journal:  J Biol Chem       Date:  2008-06-09       Impact factor: 5.157

View more
  7 in total

1.  HIV infection of astrocytes compromises inter-organelle interactions and inositol phosphate metabolism: A potential mechanism of bystander damage and viral reservoir survival.

Authors:  Shaily Malik; Silvana Valdebenito; Daniela D'Amico; Brendan Prideaux; Eliseo A Eugenin
Journal:  Prog Neurobiol       Date:  2021-08-26       Impact factor: 11.685

Review 2.  Single-Cell RNA-Sequencing: Astrocyte and Microglial Heterogeneity in Health and Disease.

Authors:  Michael S Spurgat; Shao-Jun Tang
Journal:  Cells       Date:  2022-06-24       Impact factor: 7.666

3.  Astrocyte HIV-1 Tat Differentially Modulates Behavior and Brain MMP/TIMP Balance During Short and Prolonged Induction in Transgenic Mice.

Authors:  Chaitanya R Joshi; Satomi Stacy; Nathalie Sumien; Anuja Ghorpade; Kathleen Borgmann
Journal:  Front Neurol       Date:  2020-12-15       Impact factor: 4.003

Review 4.  Human Immunodeficiency Virus Type-1 (HIV-1) Transcriptional Regulation, Latency and Therapy in the Central Nervous System.

Authors:  Joseph Hokello; Adhikarimayum Lakhikumar Sharma; Priya Tyagi; Alok Bhushan; Mudit Tyagi
Journal:  Vaccines (Basel)       Date:  2021-11-03

5.  A Non-Canonical Role for IRE1α Links ER and Mitochondria as Key Regulators of Astrocyte Dysfunction: Implications in Methamphetamine use and HIV-Associated Neurocognitive Disorders.

Authors:  Jessica Proulx; Satomi Stacy; In-Woo Park; Kathleen Borgmann
Journal:  Front Neurosci       Date:  2022-06-17       Impact factor: 5.152

Review 6.  The Glutamate System as a Crucial Regulator of CNS Toxicity and Survival of HIV Reservoirs.

Authors:  Anna Maria Gorska; Eliseo A Eugenin
Journal:  Front Cell Infect Microbiol       Date:  2020-06-24       Impact factor: 5.293

7.  β-Catenin Regulates Wound Healing and IL-6 Expression in Activated Human Astrocytes.

Authors:  Venkata Viswanadh Edara; Shruthi Nooka; Jessica Proulx; Satomi Stacy; Anuja Ghorpade; Kathleen Borgmann
Journal:  Biomedicines       Date:  2020-11-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.